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ABSTRACT
Cellular reprogramming to iPSCs has uncovered unsuspected links between 
tumor suppressors and pluripotency factors. Using this system, it was possible to 
identify tumor suppressor p27 as a repressor of Sox2 during differentiation. This led 
to the demonstration that defects in the repression of Sox2 can contribute to tumor 
development. The members of the retinoblastoma family of pocket proteins, pRb, p107 
and p130, are negative regulators of the cell cycle with tumor suppressor activity 
and with roles in differentiation. In this work we studied the relative contribution of 
the retinoblastoma family members to the regulation of Sox2 expression. We found 
that deletion of Rb or p130 leads to impaired repression of Sox2, a deffect amplified 
by inactivation of p53. We also identified binding of pRb and p130 to an enhancer 
with crucial regulatory activity on Sox2 expression. Using cellular reprogramming we 
tested the impact of the defective repression of Sox2 and confirmed that Rb deficiency 
allows the generation of iPSCs in the absence of exogenous Sox2. Finally, partial 
depletion of Sox2 positive cells reduced the pituitary tumor development initiated 
by Rb loss in vivo. In summary, our results show that Sox2 repression by pRb is a 
relevant mechanism of tumor suppression.
INTRODUCTION
Cellular reprogramming to induced pluripotency 
by the combined action of defined transcription factors is 
a powerful in vitro system to uncover basic mechanisms 
governing stem cell biology. Given the similarity between 
cellular reprogramming and oncogenic transformation [1], 
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others and us addressed the role of tumor suppressor genes 
opposing this process. In this manner, it was possible to 
identify crucial barriers impairing the efficient conversion 
of somatic cells to induced-pluripotent stem cells imposed 
by well-known tumor suppressor genes such as those 
encoded by the p53 gene and the Ink4a/Arf locus [2–6].
Further studies on the effect of other tumor 
suppressor genes in the process of cellular reprogramming 
allowed us to identify an unprecedented connection 
between a cell cycle regulator, p27, and a pluripotency 
factor, Sox2 [7]. A previously unrecognized transcriptional 
regulatory activity of p27 allows the efficient repression of 
Sox2 in differentiated cells. Loss of this regulation leads 
to unscheduled expression of Sox2 in differentiated cells 
with the drastic phenotypic consequences that characterize 
p27-null mice: gigantism, pituitary tumor development, 
and retinal defects. The transcriptional regulation of 
Sox2 during differentiation is exerted by a partially 
characterized repressive complex in which, apart from 
p27, we identified Sin3a, E2F4, and the pocket protein 
family member p130.
The retinoblastoma family of pocket proteins 
(composed by pRb, p107 and p130) is a family of negative 
regulators of the cell cycle with structural homology, 
and with overlapping and unique functions. The product 
of the RB gene is considered the member of the family 
with the most relevant tumor suppressor activity, since 
it is inactivated in a large number of human cancers [8–
12]. In addition, its deletion in mice results in tumors, 
mainly of the pituitary and the thyroid gland [13]. The 
other two family members have also been involved 
in cancer development, although their relevance is 
secondary compared to pRb [13]. In addition to its role 
in cancer, pRb controls cellular differentiation during 
embryonic development and in adult lineages [14], with 
p107 and p130 also playing regulatory roles in adult cell 
differentiation [15].
Our previous results investigating the transcriptional 
repression of Sox2 by p27 in which the pocket protein 
family member p130 was part of the repressive complex, 
together with the similarities between the process 
of reprogramming to pluripotency and oncogenic 
transformation, prompted us to investigate the role of 
the pocket protein family members in the transcriptional 
repression of Sox2. We found that deletion of Rb or p130 
leads to impaired repression of Sox2, while loss of p107 
has no apparent effect. Furthermore, we identified binding 
of pRb and p130 to an enhancer downstream of Sox2 
important for its regulation, the Sox2-SRR2 enhancer, a 
region that showed alterations in epigenetic marks upon 
loss of pocket protein family members. The functional 
consequences of the defective repression of Sox2 are 
manifested in the cellular reprogramming of Rb deficient 
cells to iPSCs in the absence of exogenous Sox2, and in 
vivo in Rb loss-driven pituitary tumor development.
RESULTS AND DISCUSSION
Cells lacking Rb or p130 express higher levels of 
Sox2
We previously showed that cell cycle regulator 
p27 contributes to the transcriptional repression of Sox2 
together with pocket protein p130 and consequently, p27 
deficient cells or shRNA-mediated knockdown of p130 
leads to an increase of Sox2 expression that has measurable 
phenotypic consequences [7]. To study in more detail the 
relative potential contribution of the pocket protein family 
members to the repression of pluripotency genes, and 
specifically to the regulation of Sox2, we measured by 
qRT-PCR the mRNA levels of Sox2 and Nanog in early 
passage primary mouse embryo fibroblasts (MEFs) derived 
from Rb-, p107-, or p130-null mice. MEFs do not express 
detectable levels of these pluripotency genes or their levels 
of expression are negligible. In contrast, the absence of Rb 
or p130 resulted in moderate but reproducibly increased 
levels of Sox2 mRNA (Figure 1A, left panel). Surprisingly, 
cells lacking Rb also showed increased levels of Nanog 
(Figure 1A, right panel), a pluripotency gene normally not 
expressed in differentiated cells.
Strikingly, when we analyzed the expression of Sox2 
in MEFs from the same genotypes immortalized by an 
shRNA targeting p53 (shp53) we observed an even higher 
increase in the expression of Sox2 specifically for MEFs 
deficient in Rb or p130, but importantly, not in wt or p107-
null cells (Figure 1B). In contrast, the increased expression 
of Nanog remained constant in Rb-deficient MEFs even 
after immortalization with shp53. Confirming these 
results, we checked Sox2 levels in MEFs immortalized by 
the expression of viral oncoprotein large-T (LT) antigen 
from SV40. LT is known for its ability to block several 
cellular functions and prominently among them, the 
tumor suppressor pathways controlled by p53 and the 
three pocket proteins [16]. In agreement with the above 
results, MEFs immortalized by LT showed an increase 
in the expression of Sox2 mRNA by qRT-PCR (Figure 
1C, upper panel), with levels high enough to allow clear 
detection of Sox2 by Western blot (Figure 1C, lower 
panel). Knockdown of p53 after shp53 expression is not 
causing an increase of Sox2 in wt cells and this seems to 
be occurring only in cells deficient in Rb or p130, that 
already underwent some form of deregulation in the 
expression of Sox2. To further explore this, we used 
reprogrammable MEFs derived from a transgenic mouse 
carrying an inducible cassette for the expression of the four 
reprogramming factors, Oct4, Sox2, Klf4 and c-Myc (i4F-
MEFs) [17]. First we introduced a pluripotency reporter 
plasmid carrying an active promoter derived from a mouse 
early transposon (ETn) that is specific for undifferentiated 
pluripotent stem cells, combined with Oct4- and Sox2-
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binding motifs (EOS)[18]. Reprogrammable MEFs 
carrying this EOS reporter plasmid showed a low level 
expression of GFP, indicative of a minor leaky expression 
from the transgenic cassette. When we expressed the 
shRNA against p53 in these i4F-MEFs carrying the EOS 
reporter plasmid a clear increase in the expression of GFP 
was evident by inspection under a fluorescent microscope. 
To verify and quantify this observation, we analyzed GFP 
expression in these cells by flow cytometry (Figure 1D, 
upper panel). In this manner, we could confirm the visual 
observation both regarding the alteration of the proportion 
of GFP positive cells (51.7% in i4F-MEFs versus 71.1% in 
i4F-MEFs-shp53), and in the intensity of GFP expression 
(mean fluorescence of 116.38 in i4F-MEFs versus 265.09 
in i4F-MEFs-shp53). In agreement with the fluorescence 
data, these cells showed by qRT-PCR a low level of Sox2 
expression that was above the levels observed in wt 
cells. These low levels of Sox2 expression were sharply 
increased when shp53 was introduced in i4F-MEFs but 
not in wt cells suggesting, again, that decreasing the 
levels of p53 amplifies the already deregulated expression 
of Sox2 (Figure 1D, lower panel), even when this initial 
Figure 1: Cells lacking Rb or p130 express higher levels of Sox2. a, Sox2 (left) or Nanog (right) mRNA levels in wt, Rb-null, 
p107-null, and p130-null primary MEFs as assessed by TaqMan expression analysis. Absolute values are referenced to the levels obtained 
with primary wt cells. b, Sox2 mRNA levels in wt, RB-null, p107-null, and p130-null immortalized fibroblasts assessed as in (a). Absolute 
values are referenced to the levels obtained with wt cells. c, Sox2 mRNA (upper panel) and protein expression by Western blot (lower panel) 
in cell extracts from wt and SV40 large-T antigen (LT) immortalized fibroblasts. Absolute values are referenced to the levels obtained 
with wt cells. d, Graph showing the analysis of GFP expression by flow cytometry from EOS pluripotency reporter plasmid introduced 
in reprogrammable primary (i4F-MEFs, black line) or immortalized (i4F-MEFs-shp53, green line) cells (upper panel). The settings were 
previously adjusted to consider i4F-MEFs without EOS plasmid as GFP negative. Sox2 mRNA levels expressed by wt or immortalized 
wt-shp53 MEFs, i4F or immortalized i4F-shp53 MEFs, and ESCs, measured by qRT-PCR (lower panel). Values are referenced to the levels 
obtained using wt primary MEFs and in log
10
 scale. All data correspond to the average ± s.d. of qRT-PCR data. Statistical significance was 
assessed by the two-tailed Student´s t-test: *** p < 0.001; ** p < 0.01; * p < 0.05; n.s. non significant.
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deregulation comes from transgenic expression. The 
increased levels observed after knockdown of p53 were 
produced not from the transgene but from the endogenous 
Sox2 locus, since they were detected using a specific 
pair of oligonucleotides for the endogenous Sox2. These 
results imply that a low level expression of Sox2 would 
be sufficient to activate its own endogenous transcription 
provided that p53 is downregulated, and point to a 
novel function for p53 blocking upregulation of Sox2 in 
differentiated cells.
Taken together, these results show a defective 
repression of Sox2 transcription in the absence of Rb or 
p130 that results in low but reproducible levels of this 
pluripotency gene in primary cells. Lack of p53 leads 
to higher expression levels of Sox2 only when they are 
originally deregulated by deficiency in Rb or p130.
pRb and p130 bind to the Sox2-SRR2 and their 
absence alters the epigenetic marks on the 
enhancer
The main regulatory element of Sox2 in pluripotent 
stem cells is an enhancer located downstream of the single 
coding exon of Sox2 gene, called SRR2, bound by Sox2 
itself and Oct4 to positively drive its expression during 
pluripotency [19]. Upon differentiation, Sox2-Oct4 on 
SRR2 are displaced by a repressive complex formed by, 
at least, p27, Sin3a, E2F4, and the pocket protein family 
member p130 that permanently occupies this regulatory 
element in somatic cells [7]. Based on this, we decided 
to look for the binding of pRb, p107, and p130 in 
differentiated cells by chromatin immunoprecipitation 
(ChIP) using extracts from MEFs. Chromatin precipitated 
using antibodies against pRb, p107 or p130 produced a 
clearly distinguishable band when subjected to PCR using 
oligonucleotides amplifying Sox2-SRR2 (Figure 2A). In 
contrast, control IgG did not produce an amplification 
band. This result implies that the three Rb family pocket 
proteins have the potential to bind to Sox2-SRR2. 
However, as shown above (Figure 1A), deficiency of p107 
does not lead to increased expression of Sox2, probably 
as a result of compensatory mechanisms by the other 
members of the family. Functional compensation among 
pocket proteins is a common feature of the family [13].
Absence of p27 from the repressive complex 
binding to Sox2-SRR2 leads to an alteration of the active 
and repressive histone marks present in the enhancer [7]. 
Given the identification of pRb and p130 bound to Sox2-
SRR2 and the derepression of Sox2 observed in these 
cells, we wondered whether a similar situation might be 
also occurring in the absence of these pocket proteins. 
To address this issue we performed ChIP assays with 
antibodies against the repressive mark H3K27me3 and the 
active mark H3K4me3 in cell extracts from MEFs deficient 
for pRB or p130, followed by qRT-PCR to quantify 
the presence of Sox2-SRR2 in the immunoprecipitates. 
Using two different sets of oligonucleotides amplifying 
Sox2-SRR2 we obtained similar results (Figure 2B). 
The repressive H3K27me3 histone mark seems to be 
reduced in cells deficient for the Rb and p130 pocket 
protein family members, while the active H3K4me3 mark 
appears increased in the absence of p130 with the two sets 
of primers, and in the absence of Rb at least when using 
Figure 2: Binding of the Rb family of pocket proteins 
to the Sox2-SRR2 enhancer and effect of their absence 
on histone marks. a, Chromatin immunoprecipitation (ChIP) 
assay using antibodies against p107, p130, and pRb followed 
by semi-quantitative PCR using primers amplifying the Sox2-
SRR2. Primers amplifying β-actin promoter and IgG were used 
as negative controls. b, ChIP of repressive H3K27me3 and active 
H3K4me3 histone marks in the Sox2-SRR2 enhancer of wt, Rb-
null, and p130-null MEFs, using two different sets of primers 
amplifying the Sox2-SRR2 enhancer (upper and middle panels). 
Control ChIP assay using primers amplifying Nanog promoter 
is shown at the bottom panel. All data correspond to the average 
± s.d. of qPCR data. Statistical significance was assessed by the 
two-tailed Student´s t-test: *** p < 0.001; ** p < 0.01; * p < 
0.05; n.s. non significant.
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one of the two sets of primers. In contrast, ChIP for these 
same histone marks in the Nanog promoter did not show 
any alteration (Figure 2B). These changes support the 
notion that lack of Rb or p130 has a specific impact on the 
epigenetic marks around the crucial Sox2-SRR2 regulatory 
element of Sox2. 
Cells lacking Rb can be reprogrammed without 
ectopic Sox2
Given the low level expression of Sox2 present in 
primary MEFs deficient for Rb we wondered whether 
this deregulated expression could have a phenotypic 
consequence that could be exposed through the use of the 
cellular reprogramming system. For this, we performed 
a cellular reprogramming experiment on wt, Rb, p107, 
or p130 deficient MEFs, with ectopic expression of 
Oct4, Klf4 and Sox2 (3F-OKS), or omitting Sox2 (2F-
OK). Control reprogramming of wt MEFs with 3F-OKS 
worked as anticipated giving rise to alkaline-phosphatase-
positive (AP+) iPSC colonies after 14 days with the 
typical morphology and at the expected rate. As predicted, 
wt cells failed to produce any colonies when only 2F-
OK were used in the reprogramming experiments. In 
contrast, when we used p130 deficient cells we obtained 
colonies both with 3F-OKS and with 2F-OK, although 
2F-OK produced colonies at much lower frequency, as 
reported [7]. Cells lacking p107 could be reprogrammed 
at approximately the same rate as wt cells with 3F-OKS 
while no colonies emerged when using 2F-OK despite 
repeated efforts. Interestingly, when we used MEFs 
Rb-null we obtained AP+ iPSC colonies not only with 
3F-OKS, as expected, but also when using 2F-OK, the 
combination omitting Sox2 (Figure 3A). The efficiency 
and kinetics of colony formation with 2F-OK were very 
low, similarly to what was previously reported and we 
confirmed when p130 deficient cells were used. To further 
prove the pluripotency of the iPSC colonies obtained, we 
introduced the EOS pluripotency reporter plasmid. EOS 
lentiviral transduction of MEFs prior to the expression 
of the reprogramming factors allowed us to observe 
the emergence of GFP positive iPSC colonies from 2F-
OK reprogrammed Rb-null MEFs (Figure 3A). These 
colonies were picked and expanded in stem cell culture 
conditions and the mRNA of Oct4, Sox2, Klf4, and Nanog 
was analyzed by qRT-PCR, confirming the expression of 
the pluripotency factors (Figure 3B). Similarly, Western 
blot analysis of protein extracts from these iPSC colonies 
showed the presence of Oct4, Sox2, and Nanog proteins 
(Figure 3C). Our Rb-null derived iPSCs with 2F-OK 
showed similar levels of mRNA or protein for all the 
pluripotency markers tested than iPSCs obtained from wt 
or Rb-null MEFs reprogrammed using 3F-OKS, or than 
control embryonic stem cells (ESCs).
Next we tested the capacity of the 2F-OK iPSCs 
from Rb-null cells to form embryoid bodies (EBs) in 
culture. For this, we used the standard hanging drop 
method to form cell aggregates that were further cultured 
in non-adherent conditions until they spontaneously 
showed contractile activity, indicative of cardiomyocyte 
differentiation. The number and size of the EBs obtained 
with 3F-OKS in wt or Rb-null, as well as with 2F-OK in 
Rb-null, was similar (Figure 3D). EBs were collected and 
RNA was extracted and analyzed by qRT-PCR for markers 
of differentiation along the three germ layers endoderm, 
mesoderm and ectoderm, confirming the pluripotent 
capacity of the iPSCs obtained (Figure 3E). In addition, 
we analyzed histologically the structures generated within 
the EBs and observed features of differentiation to the 
three germ layers (Figure 3F).
These results show that the deregulated expression 
of Sox2 in Rb deficient cells is sufficient to allow cell 
reprogramming to iPSCs without the need for exogenous 
Sox2, demonstrating that this increased expression has 
relevant functional consequences.
Partial depletion of Sox2 positive cells alleviates 
the pituitary tumor phenotype caused by reduced 
Rb in mice
Human SOX2 gene locus at 3q26.3 is amplified 
in several cancer types including glioblastoma, small-
cell lung cancer (SCLC) and many forms of squamous 
cell carcinoma (SCC) [20]. However, the involvement 
of Sox2 in cancer is not restricted to tumors showing 
gene amplification, opening up the possibility of other 
regulatory mechanisms contributing to the potential role 
of Sox2 in cancer. In this sense, we previously reported 
the contribution of Sox2 deregulated expression to the 
development of pituitary tumors in mice deficient for 
p27 [7]. Our current results were reminiscent of this 
same situation. Therefore, we wanted to determine 
if the incomplete repression of Sox2 expression in 
differentiated cells lacking Rb could contribute to tumor 
development. Heterozygosity of Rb in the mouse leads to 
the development of pituitary tumors after stochastic loss of 
the second Rb allele [21]. Given our previous results, we 
decided to measure Sox2 mRNA expression in pituitary 
tissue from wt or Rb-het mice and observed a modest 
increase in the expression of Sox2 (Figure 4A) consistent 
with our previous findings in Rb-null MEFs (Figure 1A).
To test if Sox2 positive cells contribute to the 
emergence of these tumors, we took advantage of a 
previously reported mouse model in which the thymidine 
kinase gene (TK) has been inserted into the endogenous 
Sox2 locus, the Sox2-TK mice [22]. Exposure of Sox2 
positive cells to the drug gancyclovir (GCV) induces 
cell death. Persistent exposure to GCV results in animal 
death after 1-2 weeks. However, we observed that single 
intraperitoneal injection of GCV every 2 weeks is well 
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tolerated by these mice and results in various degrees of 
Sox2 positive cell depletion. Based on this, we generated 
compound Rb-het/Sox2-TK mice and subjected them to 
a repetitive GCV administration protocol in order to test 
the contribution of Sox2 positive cells to tumors initiated 
by Rb deficiency (Figure 4B). When the treatments were 
completed we sacrificed the animals and extracted tissues 
for histological analysis. Pituitary masses were measured 
and we observed a tendency to a reduced size of pituitaries 
from Rb-het/Sox2-TK animals in the GCV-treated group 
compared to the HBSS-treated control group (Figure 4B). 
Then, we verified that we produced different degrees of 
Sox2 positive cell depletion by the GCV administration, as 
judged by Sox2 immunohistochemical staining in sections 
from control tissues, esophagus and trachea. Despite the 
low number of animals analyzed, we observed that when 
Figure 3: Absence of Rb allows two-factor (Oct4 and Klf4) reprogramming. a, Representative pictures of iPSC colonies 
expressing GFP from the EOS pluripotency reporter plasmid (top panels), and stained for alkaline phosphatase (AP, bottom panels). Shown 
are iPSC colonies obtained in wt MEFs after three-factor expression (Oct4, Klf4, and Sox2; 3F-OKS; left panel), and Rb-null MEFs 
after three-factor (3F-OKS; middle panel) or two-factor (Oct4, Klf4; 2F-OK; right panel) expression. b, Pluripotency factor (Oct4, Sox2, 
Klf4, and Nanog) mRNA expression by qRT-PCR in iPSCs obtained from wt primary MEFs reprogrammed by 3F-OKS, or Rb-null with 
3F-OKS or 2F-OK. Null expression from MEFs is shown as negative control, and expression in ESCs as positive control. c, Western blot 
analysis of the expression of pluripotency factors (Oct4, Sox2, and Nanog) in the same set of cells as in (b). d, Representative pictures of 
embryoid bodies (EBs) obtained after in vitro spontaneous differentiation of iPSCs generated from wt primary MEFs reprogrammed by 
3F-OKS, or Rb-null with 3F-OKS or 2F-OK. e, Differentiation factor (Nkx2.5, Dlx3, and Gata4) mRNA expression by qRT-PCR in EBs 
obtained from iPSCs generated from Rb-null primary MEFs reprogrammed by 2F-OK. Values are referred to the expression obtained for 
the corresponding iPSCs. All data correspond to the average ± s.d. of qRT-PCR data. Statistical significance was assessed by the two-
tailed Student´s t-test: *** p < 0.001; ** p < 0.01; * p < 0.05. f, Representative pictures of H&E stained sections of EBs obtained from 
iPSCs generated from Rb-null primary MEFs reprogrammed by 2F-OK, and embedded in paraffin. Pictures show examples of ectodermal, 
endodermal and mesodermal differentiation.
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the depletion was efficient, Rb-null pituitaries showed a 
nearly normal morphology with reduced number of Sox2 
positive cells and low cell proliferation, as judged by Ki67 
staining (Figure 4C).
Although further studies would be required, these 
results are in line with our previous observations for 
reduced pituitary size and tumor development in p27-
null mice in the context of lower Sox2 expression using 
Sox2 heterozygous mice [7]. Interestingly, although Rb is 
ubiquitously expressed and its inactivation is an extremely 
frequent event in cancer, Rb deletion in mice is a tumor-
initiating event only for some specific cell types. In this 
sense, it is tempting to speculate that Rb loss might result 
on pro-tumorigenic expression of Sox2 only for these cell 
types. Even more, according to our results concomitant 
inactivation of p53 might have synergistic effects on 
cancer by enhancing deregulated expression of genes such 
as Sox2 whose upregulation might be initiated by the loss 
of Rb.
Taken together, our results unveil an unprecedented 
mechanism of tumor initiation mediated by loss of the 
proper strict control exerted by the retinoblastoma family 
of pocket proteins on the repression of genes, such as 
Sox2, with crucial functions in regulating the properties of 
adult stem/progenitor cells.
Figure 4: In vivo effect of partial depletion of Sox2 positive cells in Rb+/- mice. a, Sox2 mRNA levels in the pituitary of wt 
(n=4) and Rb-het (n=4) mice. b, Schematic representation of the experimental protocol of gancyclovir (GCV) treatment of compound Rb-
het/Sox2-TK mice (upper panel). Intraperitoneal injections were administered at the times indicated (weeks) and mice were sacrificed when 
they were 42 weeks old. Pituitary mass (n=4 for HBSS; n=3 for GCV) of Rb-het/Sox2-TK mice (lower panel). Means ± s.e.m. are shown. 
c, Representative pictures of paraffin sections from control HBSS-treated (upper panels) or GCV-treated (lower panels) tissues from Rb-
het/Sox2-TK mice. The first three rows of pictures correspond to pituitary sections stained for H&E, proliferative marker Ki67 and Sox2, 
respectively. The two rows of pictures at the most right part correspond to control tissues, esophagus and trachea, stained for Sox2. Below 
is shown the quantification of Ki67 and Sox2 positive cells.
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MATERIALS AND METHODS
Mice and cells
Rb+/- [21], p107-/- [23], p130-/- [24], Sox2-TK 
[22], and i4F mice [17] have been previously described. 
All genotypes were maintained on a C57BL/6 and 129SvJ 
hybrid background and all comparisons were made among 
mice derived from the same sets of crosses, and they 
therefore shared the same genetic background. Animals 
were kept under SPF conditions and all experiments 
were carried out under approval of the Santiago de 
Compostela University Bioethics (protocol number 
15005AE/07/01/02/05C/AVF2) in compliance with 
Principles of Laboratory Animal Care of national laws.
Primary mouse embryo fibroblasts (MEFs, passage 
1-2) were obtained from embryos of the indicated 
genotypes, as described previously [25]. Immortalization 
was achieved by expression of an shRNA targeting mouse 
p53 [26]. Both primary and immortalized fibroblasts 
were cultured in standard DMEM medium (Sigma) 
supplemented with 10% FBS (Sigma).
ES cells and iPS cells were cultured on top of 
feeder layers in DMEM (Sigma) supplemented with 
serum replacement (KSR, 15%, LifeTechnologies), 
LIF 1000 u/ml (Millipore), 1x Non-Essential Amino 
Acids (LifeTechnologies), 1% L-glutamine (Sigma), 
1% Streptomycin/Penicillin (Sigma), and 0.1 mM 
2-mercaptoethanol (LifeTechnologies). 
Protein and RNA expression analysis
For protein expression analysis, cell extracts were 
prepared using RIPA buffer (150mM NaCl, 10mM Tris-
HCl pH 7.5, 0.1% SDS, 1% Triton X100, 5 mM EDTA 
pH 8.0, 1% Deoxycholate and sodium salt containing 
protease inhibitors), and appropriate volumes of cell 
extracts, adjusted to represent the same amount of total 
cellular protein (40 μg), were electrophoresed in 12% 
polyacrylamide gels. After electrophoretic transfer to a 
PVDF membrane at 100 V for 1 h at 4°C, the membrane 
was blocked with 5% milk in TTBS (20mM Tris-HCl 
pH7.5, 150mM NaCl, 0.05% Tween-20) for 1 h at room 
temperature. Membranes were incubated at 4ºC overnight 
with primary antibodies against SOX2 (SantaCruz, sc-
17320; 1:500), OCT4 (SantaCruz, sc-9081; 1:500), or 
NANOG (Millipore, AB 5731; 1:5000). Incubation with 
the appropriate secondary antibodies conjugated to HRP 
was followed by visualization using the ECL system.
To measure RNA expression, total RNA was 
extracted using the NucleoSpin® RNA kit (Macherey-
Nagel) following the indications of the provider and 
DNAse treatment. After nanodrop RNA quantification, 
the RNA was retrotranscribed into cDNA according to the 
manufacturer’s protocol (High-Capacity cDNA Reverse 
Transcription Kit, Applied Biosystems). Quantitative 
Real Time-PCR was performed using SYBR Green 
Power PCR Master Mix (Applied Biosystems) in an 
Mx3005P real-time PCR system (Agilent technologies 
Stratagene). Relative quantitative RNA was normalized 
using the housekeeping gene GADPH. Primer sequences 
are available from the authors upon request. For specific 
experiments, TaqMan Real Time-PCR was performed 
using GoTaq® Probe qPCR Master Mix (Promega) in a 
StepOne™ and StepOnePlus™ PCR Real-Time System 
(Applied Biosystems). Relative quantitative RNA was 
normalized using the housekeeping gene UBC. The 
TaqMan® probes used were: Sox2 (Mm03053810_s1), 
Nanog (Mm02384862_g1).
Chromatin immunoprecipitation
To identify the binding of the pocket proteins to 
the Sox2-SRR2 enhancer, cells were harvested at 90% 
confluence and fixed by adding 1/10 of fixation solution 
(0,1M NaCl, 1mM EDTA, 0.5mM EGTA, 50mM Hepes 
pH8.0 and 11% Formaldehyde) to the culture media for 
15 min at room temperature. Crosslinking was stopped 
by the addition of glycine to a final concentration of 
0.125 M. Fixed cells were sonicated in lysis buffer (0.5% 
NP-40, 1% Triton X-100, 5 mM EDTA, 50 mM Tris-
HCl pH 7.5, 150 mM NaCl plus protease inhibitors). 
For immunoprecipitation, 150 μg of chromatin were 
diluted in dilution buffer (1% Triton X-100, 0.1% 
sodium deoxycholate, 140 mM NaCl, 1 mM EDTA, 0.5 
mM EGTA and 10 mM Tris-HCl, pH 8.0, containing 
protease inhibitors) and pre-cleared with blocked protein 
G-sepharose (GE Healthcare). An aliquot of 50 μg of 
chromatin was reserved as input. The antibodies used 
for the immunoprecipitation were pRb1 (Santa Cruz, 
C-15), p107 (Santa Cruz, C-18), p130 (Santa Cruz, C-20), 
and normal rabbit IgG (Santa Cruz, sc-2027). Immune 
complexes were precipitated with protein G-sepharose 
and washed sequentially with low-salt wash buffer (0.1% 
SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 
8.1, 150 mM NaCl), high-salt wash buffer (0.1% SDS, 1% 
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1, 500 
mM NaCl), LiCl wash buffer (0.25 M LiCl, 1% NP-40, 
1% deoxycholate-Na, 1 mM EDTA, 10 mM Tris-HCl pH 
8.1) and TE buffer. Immunoprecipitated DNA was eluted 
in elution buffer (1% SDS, 0.1 M NaHCO3) and extracted 
using the Wizard SV Gel and PCR System (Promega). 
PCR was carried out using 5 μL of each sample except for 
the input that was previously diluted. 
The primers used for PCR were:
Sox2-SRR2-F: 
5’-ATTTATTCAGTTCCCAGTCCAAGC-3’
Sox2-SRR2-R: 5’-CCCTCTCCCCCCACGC-3’
β-actin-F: 
5’-CAGTTCGCCATGGATGACGATATC-3’
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β-actin-R: 
5’-CCGCGAACCCGGCTTTGCACATG-3’ 
The analysis of histone marks was performed 
essentially as described [27]. Briefly, wt, RB-null, and 
p130-null MEFs were trypsinized and cross-linked in 1% 
formaldehyde (Sigma) for 10 min at room temperature 
(RT). Crosslinking was quenched with 0.125 M glycine 
for 5 min. Pelleted cells were lysed in 1 ml ChIP buffer 
and sonicated for 10 min in a Bioruptor (Diagenode). 
Soluble material was quantified by Bradford assays. 
100 μg of chromatin were used to immunoprecipitate 
histone modifications. The antibodies H3K27me3 
(Millipore, 07-449) and H3K4me3 (Diagenode, pAb003-
050) were incubated overnight with the chromatin. 
Immunocomplexes were recovered with 30 μl of protein 
A or G-agarose bead slurry. Immunoprecipitated material 
was washed three times with low salt buffer and one time 
with high salt buffer DNA complexes were decrosslinked 
at 65°C for 3 h, and DNA was then eluted in 200 μl of 
water using the PCR purification kit (QIAGEN). Two 
microliters of DNA was used for each qPCR reaction 
using SYBR green (Fermentas).
The primers used for Sox2-SRR2 were the ones 
shown above plus an extra set of primers: 
Sox2-SRR2-F: 
5’-CGTGGTAATGAGCACAGTCG-3’
Sox2-SRR2-R: 
5’-AGGCTGAGTCGGGTCAATTA-3’
The primers used for Nanog promoter were:
Nanog-promoter-F: 
5’-CAACTTACTAAGGTAGCCCGAGTCTTAA-3’
Nanog-promoter-R: 
5’-CCTCCAAAAGTGCGGCTTT-3’
Cellular reprogramming to iPSCs
Reprogramming of primary (passage 1-2) MEFs 
was performed using plasmids pMXs-Oct4, pMXs-Klf4, 
and pMXs-Sox2 [28] essentially as described [7]. Briefly, 
retroviral supernatants were produced in HEK-293T cells 
(3x106 cells per 100-mm-diameter dish) transfected by the 
calcium chloride protocol with the ecotropic packaging 
plasmid pCL-Eco (5 µg) together with the reprogramming 
factors (5 µg) in combinations of 3 (Oct4, Klf4, and Sox2) 
or 2 (Oct4 and Klf4) factors. Retroviral supernatants 
(10 ml) were collected serially 48 h later and during 36 
h, each time adding fresh medium to the cells (10 ml). 
The recipient MEFs had been seeded the previous day 
(1.4x106 cells per 100-mm-diameter dish) and received 2.5 
mL of each of the corresponding retroviral supernatants. 
This procedure was repeated every 12 hours for a total 
of 3 additions. After infection was completed, media was 
replaced by iPS cell medium (see above).
For alkaline phosphatase (AP) staining the iPSCs 
colonies were fixed with 4 % paraformaldehyde and the 
alkaline phosphatase activity was detected with BCIP 
(5-bromo-4-chloro-3-indolyl-phosphate)/NBT(nitro blue 
tetrazolium) Color Development Substrate (Promega) 
according to the manufacturer’s instructions.
The lentiviral pluripotency reporter plasmid PL-
SIN-EOS-C(3+)-EiP (Addgene #21313) [18] was used to 
visualize the emergence of iPSC colonies by inspection 
of GFP expression using a fluorescence microscope. 
Lentiviral transduction with this plasmid was performed 
after co-transfection of packaging vectors psPAX2 and 
VSVG in HEK-293T cells as described for retroviral 
infections.
In vitro embryoid body differentiation
To test pluripotency of the iPSC colonies generated 
we performed in vitro embryoid body differentiation 
assays using the hanging drop technique. For this, iPSCs 
cells were trypsinized and counted. After removing trypsin, 
iPSCs were resuspended at a density of 2.5x105 cells/mL 
in Embryoid Body medium: DMEM supplemented with 
10% FBS, 1% Streptomycin/Penicillin, 1% L-Glutamine, 
0.1 mM 2-mercaptoethanol and 1X Non-Essential Amino 
Acids. Small volumes of 20 μl were plated as droplets on 
the lid of the Petri dish and an average of 50 hanging drops 
were cultured over a cell culture dish containing PBS. 
After 3 days, droplets were collected and transferred to a 
Petri dish and further cultured in Embryoid Body medium 
for 15 days before harvested for qRT-PCR and histological 
analysis.
To analyze histological differentiation, EBs were 
included in melted agar and the resulting plug was fixed in 
buffered formalin at 4ºC, embedded in paraffin wax, and 
sectioned at a thickness of 5 µm. Sections were stained 
with hematoxylin and eosin for pathological examination.
In vivo experiments
Starting at 6 weeks of age, compound Rb-het/
Sox2-TK mice were intraperitoneally injected with 
gancyclovir (GCV) at 100 mg/Kg in HBSS (Cymevene, 
Roche Pharmaceuticals) or vehicle (HBSS) every 2 weeks 
during the first 20 weeks of life, and then switched to 
single injections every 4 weeks, to complete a total of 
12 injections. Animals were sacrificed when they were 
42 weeks old, tissues were removed, and pituitaries were 
weighted before processing for immunohistochemistry.
For immunohistochemical analysis, tissue was 
fixed in formalin at 4ºC, embedded in paraffin wax, and 
sectioned at a thickness of 5 µm. Sections were stained 
with hematoxylin and eosin for pathological examination 
or processed for immunohistochemical analysis with 
antibodies against mouse Ki67 (Master Diagnostica, SP6), 
or Sox2 (CST #3728, C70B1).
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